Published in Hepatitis Weekly, April 5th, 2004
The patient will be treated at the Sydney melanoma unit at the Royal Price Alfred Hospital in Sydney, Australia, the initial clinical site for the company's pivotal trial.
"This is an important milestone for our company and marks the beginning of our final step toward FDA [U.S. Food and Drug Administration] approval," said M.S. Koly, CEO of Delcath. "Now that the first patient is enrolled, the clinical team in Sydney indicated to us that future enrollments should happen at a more rapid pace."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.